Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung

NCT01466660 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01466660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01466660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LUX-Lung 7: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
December 13, 2011
Completion date
April 12, 2019
Enrollment
319 (actual)
Sites
63

Conditions

As the registry lists them; a condition with its own page is linked.

lung neoplasms